Eli Lilly Misses Third-Quarter Profit Amid Soaring Demand for Weight-Loss Drug

7
2
Favorite

Eli Lilly Misses Third-Quarter Profit Amid Soaring Demand for Weight-Loss Drug

TH-Reuters10-30

Oct 30 (Reuters) - Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.

The company earned $1.18 per share on an adjusted basis for the quarter ended Sept.30, compared with analysts' average estimate of $1.47, according to LSEG data.

The shares plunged 10% in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（2）

Mr Bull
·10-30
Good opportunity to accumulate. missing the numbers is not due to non- performance.
Reply
1
Report
Bharatt
·10-30
Share your opinion about this news…
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1100174443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100174443","market":"us","top_or_hot":-1,"title":"Eli Lilly Misses Third-Quarter Profit Amid Soaring Demand for Weight-Loss Drug","media":"TH-Reuters","content":"<html><head></head><body><p>Oct 30 (Reuters) - Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.</p><p>The company earned $1.18 per share on an adjusted basis for the quarter ended Sept.30, compared with analysts&#39; average estimate of $1.47, according to LSEG data.</p><p>The shares plunged 10% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/9f9f79949672815489a6952a8ea54f02\" tg-width=\"538\" tg-height=\"160\"/></p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Misses Third-Quarter Profit Amid Soaring Demand for Weight-Loss Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Misses Third-Quarter Profit Amid Soaring Demand for Weight-Loss Drug\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-30 18:50 北京时间&nbsp;&nbsp;&nbsp;<strong>TH-Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 30 (Reuters) - Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1100174443","we_media_id":"1006801671","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100174443","pubTimestamp":1730285451,"sourceInfo":null,"weMediaInfo":{"media_name":"TH-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1006801671","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oct 30  - Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.The company earned $1.18 per share on an adjusted basis for the quarter ended Sept.30, compared with analysts' average estimate of $1.47, according to LSEG data.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"由于减肥药需求飙升，礼来公司第三季度利润未达预期","themeId":"da5dee29c4cbc01ed384e6cca65e9c01","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Oct 30 (Reuters) - Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.The company earned $1.18 per share on an adjusted basis for the quarter ended Sept.30, compared with analysts' average estimate of $1.47, according to LSEG data.The shares plunged 10% in premarket trading.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":365716347564064,"gmtCreate":1730286892478,"gmtModify":1730286896278,"author":{"id":"4128923481696492","authorId":"4128923481696492","name":"Mr Bull","avatar":"https://community-static.tradeup.com/news/b479a776ac6b637ec22ebd8548a46164","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"4128923481696492","authorIdStr":"4128923481696492"},"htmlText":"Good opportunity to accumulate. missing the numbers is not due to non- performance.&nbsp;","listText":"Good opportunity to accumulate. missing the numbers is not due to non- performance.&nbsp;","text":"Good opportunity to accumulate. missing the numbers is not due to non- performance.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365716347564064","repostId":1100174443,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":365714199589080,"gmtCreate":1730286359062,"gmtModify":1730286362927,"author":{"id":"4110517357648632","authorId":"4110517357648632","name":"Bharatt","avatar":"https://community-static.tradeup.com/news/01b61334ecaa34be386b848cc6733aa1","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"4110517357648632","authorIdStr":"4110517357648632"},"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365714199589080","repostId":1100174443,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":7,"commentSize":2,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}